e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Pulmonary hypertension: novel clinical insights
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1
Ioana Preston (Boston, United States of America), Ioana Preston, Nadine Al-Naamani, Stefano Ghio, Hossein-Ardeschir Ghofrani, Paul Hassoun, Sylvia Nikkho, Arno Fritsch, Adam Torbicki
Source:
International Congress 2015 – Pulmonary hypertension: novel clinical insights
Session:
Pulmonary hypertension: novel clinical insights
Session type:
Poster Discussion
Number:
2103
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ioana Preston (Boston, United States of America), Ioana Preston, Nadine Al-Naamani, Stefano Ghio, Hossein-Ardeschir Ghofrani, Paul Hassoun, Sylvia Nikkho, Arno Fritsch, Adam Torbicki. Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1. Eur Respir J 2015; 46: Suppl. 59, 2103
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study
Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Year: 2017
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Pulmonary arterial hypertension in patients treated with interferon
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH)
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Assessment of simvastatin treatment on pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Pregnancy and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept